OncoSec Medical Inc (ONCS)-医療機器分野:企業M&A・提携分析

◆英語タイトル:OncoSec Medical Inc (ONCS) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011394
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. It is also identifying and developing novel immune-targeting agents for use with the ImmunoPulse platform. The company conducts pre-clinical and clinical studies targeting various cancers in collaboration with various academic medical centers and companies. OncoSec is headquartered in San Diego, California, the US.

OncoSec Medical Inc (ONCS) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OncoSec Medical Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
OncoSec Medical Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
OncoSec Medical Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
OncoSec Medical Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
OncoSec Medical Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
OncoSec Medical Inc, Medical Equipment, Deal Details 11
Partnerships 11
OncoSec Medical Enters into Agreement with Jounce Therapeutics 11
OncoSec Medical Enters into Agreement with Inhibrx 12
OncoSec Medical Enters into Research Agreement with University of California and PerkinElmer 13
OncoSec Medical Enters Into Research Agreement With Serametrix 14
Equity Offering 15
OncoSec Medical Plans to Raise up to USD16 Million in Public Offering of Shares 15
OncoSec Medical to Raise USD9.3 Million in Private Placement of Shares upon Exercise of Warrants 16
OncoSec Medical Raises USD7 Million in Private Placement of Shares 17
Oncosec Medical Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 19
OncoSec Medical Plans to Raise up to USD8.4 Million in Public Offering of Shares 20
OncoSec Medical Raises USD10 Million in Registered Direct Offering 21
OncoSec Medical Raises USD13.6 Million in Private Placement of Shares 22
OncoSec Medical Raises USD16 Million in Private Placement of Shares and Warrants 23
OncoSec Medical Completes Private Placement Of Shares For US$12 Million 24
OncoSec Medical Completes Private Placement Of Common Stock For US$7 Million 25
OncoSec Medical Completes Public Offering Of Units For US$8 Million 26
OncoSec Medical Completes Private Placement Of US$3 Million 28
OncoSec Medical Completes Private Placement Of US$1.09 Million 29
OncoSec Medical Inc – Key Competitors 30
OncoSec Medical Inc – Key Employees 31
OncoSec Medical Inc – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Financial Announcements 33
Jun 01, 2017: OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2017 33
Mar 16, 2017: OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2017 35
Dec 08, 2016: OncoSec Announces First Quarter Financial Results for Fiscal Year 2017 36
Oct 13, 2016: OncoSec Announces Fourth Quarter and Year End Results for Fiscal Year 2016 37
Jun 09, 2016: OncoSec Announces Third Quarter and YTD Results for Fiscal Year 2016 38
Mar 08, 2016: OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2016 and Calendar 2016 Milestones 39
Corporate Communications 40
Dec 05, 2017: OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to CSO 40
Nov 07, 2017: OncoSec Appoints Daniel J. O’Connor as Chief Executive Officer to Lead Next Stage of Growth as a Fully Integrated Late Stage Development and Commercial Company 41
Sep 07, 2017: OncoSec Appoints Industry Leader Daniel J. O’Connor to its Board of Directors 42
Sep 06, 2016: OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer 43
Apr 15, 2016: OncoSec Announces New Senior Leadership Responsibilities 44
Feb 29, 2016: OncoSec Appoints Sharron Gargosky, PhD, as Head of Clinical Development and Operations 45
Product News 46
Nov 28, 2017: OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform 46
May 02, 2017: OncoSec to Present at Biomarkers & Immuno-Oncology World Congress 2017 47
Jun 28, 2016: OncoSec Presents Significant Advancements in Electroporation Technology for Immunotherapy 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
OncoSec Medical Inc, Medical Equipment, Key Facts, 2017 2
OncoSec Medical Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
OncoSec Medical Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
OncoSec Medical Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
OncoSec Medical Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
OncoSec Medical Inc, Deals By Market, 2011 to YTD 2017 9
OncoSec Medical Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
OncoSec Medical Enters into Agreement with Jounce Therapeutics 11
OncoSec Medical Enters into Agreement with Inhibrx 12
OncoSec Medical Enters into Research Agreement with University of California and PerkinElmer 13
OncoSec Medical Enters Into Research Agreement With Serametrix 14
OncoSec Medical Plans to Raise up to USD16 Million in Public Offering of Shares 15
OncoSec Medical to Raise USD9.3 Million in Private Placement of Shares upon Exercise of Warrants 16
OncoSec Medical Raises USD7 Million in Private Placement of Shares 17
Oncosec Medical Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 19
OncoSec Medical Plans to Raise up to USD8.4 Million in Public Offering of Shares 20
OncoSec Medical Raises USD10 Million in Registered Direct Offering 21
OncoSec Medical Raises USD13.6 Million in Private Placement of Shares 22
OncoSec Medical Raises USD16 Million in Private Placement of Shares and Warrants 23
OncoSec Medical Completes Private Placement Of Shares For US$12 Million 24
OncoSec Medical Completes Private Placement Of Common Stock For US$7 Million 25
OncoSec Medical Completes Public Offering Of Units For US$8 Million 26
OncoSec Medical Completes Private Placement Of US$3 Million 28
OncoSec Medical Completes Private Placement Of US$1.09 Million 29
OncoSec Medical Inc, Key Competitors 30
OncoSec Medical Inc, Key Employees 31

★海外企業調査レポート[OncoSec Medical Inc (ONCS)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • P. H. Glatfelter Company (GLT):企業の財務・戦略的SWOT分析
    P. H. Glatfelter Company (GLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Banque Cantonale de Geneve Private Banking:企業の戦略・SWOT・財務分析
    Banque Cantonale de Geneve Private Banking - Strategy, SWOT and Corporate Finance Report Summary Banque Cantonale de Geneve Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • John Menzies Plc
    John Menzies Plc - Strategy, SWOT and Corporate Finance Report Summary John Menzies Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Statkraft AS:企業の戦略・SWOT・財務分析
    Statkraft AS - Strategy, SWOT and Corporate Finance Report Summary Statkraft AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Neusoft Corporation (600718):企業の財務・戦略的SWOT分析
    Neusoft Corporation (600718) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • The Shipping Corporation of India Ltd (SCI):企業の財務・戦略的SWOT分析
    The Shipping Corporation of India Ltd (SCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Daqo New Energy Corp (DQ)-エネルギー分野:企業M&A・提携分析
    Summary Daqo New Energy Corp (Daqo Cayman) is a manufacturer of polysilicon and solar wafers. Through tolling agreements, the company also offers wafer original equipment manufacturer (OEM) services to external customers. It sells its products to solar cell and solar module manufacturers. Daqo Cayma …
  • Jungheinrich AG:戦略・SWOT・企業財務分析
    Jungheinrich AG - Strategy, SWOT and Corporate Finance Report Summary Jungheinrich AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Southern California Edison Co:企業の発電所・SWOT分析2018
    Southern California Edison Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Industrias Nucleares do Brasil SA:企業の戦略的SWOT分析
    Industrias Nucleares do Brasil SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Rev1 Ventures Inc.:企業のM&A・事業提携・投資動向
    Rev1 Ventures Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Rev1 Ventures Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Avanti Energy Inc (AVN):企業の財務・戦略的SWOT分析
    Summary Avanti Energy Inc (Avanti Energy), formerly known as Overlord Capital Ltd is an oil and gas exploration and production company. The company acquires, explores, and develops gas reserves in Central Italy. It re-develops the existing oil and gas reserves. Avanti Energy owns the Colle Santo gas …
  • Diagnostic & Therapeutic Center of Athens Hygeia SA (HYGEIA):企業の財務・戦略的SWOT分析
    Diagnostic & Therapeutic Center of Athens Hygeia SA (HYGEIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the com …
  • HearMeOut Ltd (HMO):企業の財務・戦略的SWOT分析
    HearMeOut Ltd (HMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Abeona Therapeutics Inc (ABEO)-医療機器分野:企業M&A・提携分析
    Summary Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company focusing on the development and delivery of gene therapy and plasma-based products for severe and life-threatening rare diseases. The company’s lead programs include ABO-101 and ABO …
  • bioLytical Laboratories Inc:製品パイプライン分析
    Summary bioLytical Laboratories Inc (bioLytical) is a medical device company that develops and manufactures HIV diagnostic products. The company offers products such as insti HIV-1/HIV-2 antibody test and insti HIV-1/HIV-2 test controls. Its product line provides test results that translates into a …
  • Guangdong Biolight Meditech Co Ltd (300246):医療機器:M&Aディール及び事業提携情報
    Summary Guangdong Biolight Meditech Co Ltd (Biolight) is a medical device company. The company operates in the business of research, development, production and sale of medical treatment monitors, medical consumables and healthcare solutions. It offers patient monitors, hemodialysis products and hom …
  • Torchmark Corp:企業の戦略・SWOT・財務情報
    Torchmark Corp - Strategy, SWOT and Corporate Finance Report Summary Torchmark Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Thirau Inc.:企業の戦略的SWOT分析
    Thirau Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Therapix Biosciences Ltd (TRPX):製薬・医療:M&Aディール及び事業提携情報
    Summary Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapix’s major product candidates include THX-110, for the trea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆